<DOC>
	<DOCNO>NCT02160054</DOCNO>
	<brief_summary>To evaluate safety efficacy Graceptor ® patient kidney transplantation convert cyclosporine</brief_summary>
	<brief_title>Specified Drug Use-results Survey Graceptor Patients With Kidney Transplantation ( Switching From Cyclosporine )</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients convert Graceptor® cyclosporine maintenance phase kidney transplantation . Patients meet one follow criterion 1 . Decrease kidney function : GFR ( eGFR ) less 60 mL/min , investigator 's decision 2 . Hypertension : systolic/diastolic blood pressure 130/80 mmHg treatment antihypertensive drug 3 . Hyperlipidaemia : LDL cholesterol 120 mg/dL , treatment antihyperlipidemic drug 4 . Rejection : antibody mediate rejection Banff classification borderline change severe , investigator 's decision 5 . Other adverse event patient continue cyclosporine treatment base investigator 's decision</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>Graceptor®</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>